Literature DB >> 21116295

Chemotherapy: Failure of bevacizumab in early-stage colon cancer.

Daniel J Sargent.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21116295     DOI: 10.1038/nrclinonc.2010.205

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

2.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Linda H Colangelo; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Richard M Goldberg; Seamus O'Reilly; Luis Chu; Catherine A Azar; Samia Lopa; Norman Wolmark
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

3.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

4.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

6.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

7.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

Authors:  Richard Gray; Jennifer Barnwell; Christopher McConkey; Robert K Hills; Norman S Williams; David J Kerr
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321

  7 in total
  2 in total

Review 1.  Reappraising antiangiogenic therapy for breast cancer.

Authors:  Robert S Kerbel
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

2.  Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells.

Authors:  Francesca Bianchini; Silvia Peppicelli; Pierangelo Fabbrizzi; Alessio Biagioni; Benedetta Mazzanti; Gloria Menchi; Lido Calorini; Alberto Pupi; Andrea Trabocchi
Journal:  Mol Cell Biochem       Date:  2016-10-19       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.